AstraZeneca PLC ADR (AZN): Price and Financial Metrics

AstraZeneca PLC ADR (AZN): $68.53

0.26 (+0.38%)

POWR Rating

Component Grades

Momentum

C

Stability

B

Sentiment

Quality

B

Add AZN to Watchlist
Sign Up

AZN Price/Volume Stats

Current price $68.53 52-week high $76.56
Prev. close $68.26 52-week low $60.47
Day low $68.20 Volume 3,709,808
Day high $68.80 Avg. volume 6,207,281
50-day MA $66.05 Dividend yield 2.8%
200-day MA $66.60 Market Cap 212.47B

AZN Stock Price Chart Interactive Chart >


AstraZeneca PLC ADR (AZN) Company Bio


AstraZeneca plc engages in the discovery, development, and commercialization of prescription medicines for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection, and neuroscience diseases worldwide. The company was founded in 1992 and is based in London, the United Kingdom.


AZN Latest News Stream


Event/Time News Detail
Loading, please wait...

AZN Latest Social Stream


Loading social stream, please wait...

View Full AZN Social Stream

Latest AZN News From Around the Web

Below are the latest news stories about ASTRAZENECA PLC that investors may wish to consider to help them evaluate AZN as an investment opportunity.

Buy AstraZeneca Stock. It Looks Much Better Going Into 2024.

The Big Pharma mainstay is set to deliver double-digit earnings growth, driven by a diverse portfolio of blockbusters and promising newcomers.

Yahoo | December 28, 2023

Why Is Cytokinetics (CYTK) Stock Up 70% Today?

With Cytokinetics hitting a homerun with its heart failure drug, CYTK stock skyrocketed in part due to takeover interest.

Josh Enomoto on InvestorPlace | December 27, 2023

Astrazeneca (AZN) Surpasses Market Returns: Some Facts Worth Knowing

In the most recent trading session, Astrazeneca (AZN) closed at $67.35, indicating a +1.28% shift from the previous trading day.

Yahoo | December 27, 2023

Recent M&A Bodes Well For Targeted Cancer Therapy Player Fusion Pharmaceuticals, Analyst Say AstraZeneca Is Favorably Positioned

With recent merger and acquisition deals in the targeted radiopharmaceutical therapy (TRT) space, on Tuesday, Oppenheimer noted that Fusion Pharmaceuticals Inc (NASDAQ: FUSN) is potentially the sole remaining clinical-stage player with a robust supply chain. In September, Oppenheimer initiated coverage on Fusion Pharmaceuticals, citing the company's pipeline as among the best in the space with alpha-emitter-based targeted radionuclide therapies. Most recently, Bristol Myers Squibb & Co (NYSE: BM

Yahoo | December 27, 2023

AstraZeneca (AZN) Set to Acquire Gracell for $1.2 Billion

AstraZeneca (AZN) is set to acquire clinical-stage biopharmaceutical company, Gracell, for a total deal value of up to $1.2 billion.

Yahoo | December 27, 2023

Read More 'AZN' Stories Here

AZN Price Returns

1-mo 4.07%
3-mo 4.57%
6-mo 8.98%
1-year -6.68%
3-year 44.31%
5-year 99.65%
YTD 3.28%
2023 1.40%
2022 19.10%
2021 19.66%
2020 3.06%
2019 35.58%

AZN Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full AZN Dividend History

Continue Researching AZN

Here are a few links from around the web to help you further your research on Astrazeneca Plc's stock as an investment opportunity:

Astrazeneca Plc (AZN) Stock Price | Nasdaq
Astrazeneca Plc (AZN) Stock Quote, History and News - Yahoo Finance
Astrazeneca Plc (AZN) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!